Boundless Bio (BOLD)

• Market cap: $26.2M
• 1 day: 3.54%
• 5 days: 1.74%
• 1 month: 5.41%
• 3 months: -5.65%
• 6 months: -10%
• Year to date: -4.1%
• 1 year: -5.65%
• 5 years: -91.79%
• 10 years: -91.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Employees: 28